Evidence map›Paper›PMID 36330490›Full record

ArticleFrontiers in oncology2022

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma.

Yonggang Wang, Chang Wang, Yanqiao Zhang, Jiqing Hao, Nong Yang, Jvfeng Wang, Min Peng, Tianshu Liu, Guifang Zhang, Xianbao Zhan and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02764268 (Apatinib Dose Titration), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02764268 nacompletednot on this map

Apatinib Dose Titration: Analyses of Exposure, Safety and Efficacy in Advanced or Metastatic Gastric Cancer

TypeinterventionalSponsorJiangsu HengRui Medicine Co., Ltd.Ran2016 to 2019Enrolled60ConditionsGastric CancerArmsApatinib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yonggang WangDepartment of Oncology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai, China.
Chang WangTumor Center, The First Hospital of Jilin University, Changchun, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jiqing HaoDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Nong YangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
Jvfeng WangDepartment of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Min PengDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Tianshu LiuDepartment of Oncology, Zhongshan Hospital Fudan University, Shanghai, China.
Guifang ZhangDepartment of Oncology, Xinxiang Central Hospital, Xinxiang, China.
Xianbao ZhanDepartment of Oncology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Shan ZengDepartment of Oncology, Xiangya Hospital Central South University, Changsha, China.
Yifan ZhangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yong GaoDepartment of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yang YaoDepartment of Oncology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: The objective of this study was to investigate the pharmacokinetics, safety, and antitumor activity of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and evaluate the effect of dose titration on dosage optimization for individual patients. Methods: Patient with advanced gastric adenocarcinoma progressed after at least one line of chemotherapy were enrolled. Apatinib was given orally once daily starting at 500 mg for 14 days, then up-titrated to 750 mg for 14 days, and then proceeded to a maximum dose of 850 mg. Dose up-titration determination was based on toxicity. The 28-day treatment cycles continued until disease progression, intolerable toxicities, withdrawal of consent, or investigator' decision. Results: A total of 60 patients were enrolled, with 17, 18, and 25 patients receiving a maximum dose of 500 mg, 750 mg, and 850 mg, respectively. The pharmacokinetic parameters varied considerably, with the interpatient coefficient of variation for steady state areas under the plasma concentration time curve (AUC Conclusions: Apatinib dose titration based on toxicity could be used in clinical practice to provide optimal dosage for individual patients. Clinical Trial registration: https://clinicaltrials.gov/ct2/show/NCT02764268?term=NCT02764268&draw=2&rank=1, NCT02764268.

Indexed as

angiogenesisapatinibgastric adenocarcinomapharmacokineticsVEGFRVEGFR-2

Identifiers

PMID36330490
PMCPMC9623328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.